Photo of Robert J. Gray,  PhD

Robert J. Gray, PhD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-3012
Fax: (617) 632-2444


gray@jimmy.harvard.edu

Robert J. Gray, PhD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Professor, Biostatistics, Harvard T.H. Chan School Of Public Health
  • Professor, Biostatistics and Computational Biology, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

My major research activities involve the design and analysis of clinical trials and the study of related statistical issues. As head of the Statistical Center for the Eastern Cooperative Oncology Group, I lead a group involved annually in the design and analysis of dozens of cancer clinical trials in most types of adult malignancies. These studies often include extensive biological correlative endpoints and quality of life evaluations in addition to primary efficacy evaluations. Some areas of current interest in statistical methodology include methods of adjustment for treatment noncompliance, design and analysis of studies with competing risks endpoints, dependent censoring related to incomplete follow-up of disease status, issues related to the interim analysis and monitoring of clinical trials, and analysis of high-dimensional laboratory data.

Publications

Powered by Harvard Catalyst
  • Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, Cherbavaz DB, Shak S, Page DL, Sledge GW, Davidson NE, Ingle JN, Perez EA, Wood WC, Sparano JA, Badve S. A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast. Journal of the National Cancer Institute 2013. PubMed
  • Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L, Jiang G, Miller KD, Gralow JR, Dickler MN, Cobleigh MA, Perez EA, Shenkier TN, Vang Nielsen K, Müller S, Thor A, Sledge GW, Sparano JA, Davidson NE, Badve SS. Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res 2013; 19:1281-9. PubMed
  • Dodd LE, Korn EL, Freidlin B, Gu W, Abrams JS, Bushnell WD, Canetta R, Doroshow JH, Gray RJ, Sridhara R. An audit strategy for time-to-event outcomes measured with error: Application to five randomized controlled trials in oncology. Clin Trials 2013; 10:754-60. PubMed
  • Tevaarwerk AJ, Gray RJ, Schneider BP, Smith ML, Wagner LI, Fetting JH, Davidson N, Goldstein LJ, Miller KD, Sparano JA. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: Little evidence of improvement over the past 30 years. Cancer 2012. PubMed
  • Dodd LE, Korn EL, Freidlin B, Gray R, Bhattacharya S. An Audit Strategy for Progression-Free Survival. Biometrics 2011. PubMed
  • Brahmer JR, Dahlberg SE, Gray RJ, Schiller JH, Perry MC, Sandler A, Johnson DH. Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 459 J Thorac Oncol 2010; 6:103-8. PubMed
  • Wang R, Lagakos SW, Gray RJ. Testing and interval estimation for two-sample survival comparisons with small sample sizes and unequal censoring. Biostatistics 2010; 11:676-92. PubMed
  • Schroen AT, Petroni GR, Wang H, Gray R, Wang XF, Cronin W, Sargent DJ, Benedetti J, Wickerham DL, Djulbegovic B, Slingluff CL. Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clin Trials 2010; 7:312-21. PubMed
  • Freidlin B, Korn EL, Gray R. A general inefficacy interim monitoring rule for randomized clinical trials. Clin Trials 2010; 7:197-208. PubMed
  • Gor PP, Su HI, Gray RJ, Gimotty PA, Horn M, Aplenc R, Vaughan WP, Tallman MS, Rebbeck TR, Demichele A. Cyclophosphamide- metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Res 2010; 12:R26. PubMed
  • Bhattacharya S, Fyfe G, Gray RJ, Sargent DJ. Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials. J Clin Oncol 2009; 27:5958-64. PubMed
  • Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009; 27:4966-72. PubMed
  • Agarwala SS, Gray RJ, Wong MK. Duration of high-dose interferon alpha-2b regimen for resected high-risk melanoma. J Clin Oncol 2009; 27:e82-3; author reply e84. PubMed
  • Gray RJ. Weighted analyses for cohort sampling designs. Lifetime Data Analysis 2009. PubMed
  • Sandler AB, Schiller JH, Gray R, Dimery I, Brahmer J, Samant M, Wang LI, Johnson DH. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol 2009; 27:1405-12. PubMed
  • Gray RJ. Weighted analyses for cohort sampling designs. Lifetime Data Analysis 2008; 15:24-40. PubMed
  • Ruan PK,Gray RJ. Analyses of cumulative incidence functions via non-parametric multiple imputation. Stat Med 2008; 27:5709-24. PubMed
  • Dahlberg SE,Gray RJ,Johnson BE. Gefitinib for recurrent non-small-cell lung cancer: all things are not created equal. J Clin Oncol 2008; 26:4233-5. PubMed
  • Sarojini H, Estrada R, Lu H, Dekova S, Lee MJ, Gray RD, Wang E. PEDF from mouse mesenchymal stem cell secretome attracts fibroblasts. J Cell Biochem 2008; 104:1793-802. PubMed
  • Freidlin B, Korn EL, Gray R, Martin A. Multi-arm clinical trials of new agents: some design considerations. Clin Cancer Res 2008; 14:4368-71. PubMed
  • Mekmaysy CS, Petraccone L, Garbett NC, Ragazzon PA, Gray R, Trent JO, Chaires JB. Effect of O(6)-Methylguanine on the Stability of G-Quadruplex DNA. J Am Chem Soc 2008; 130:6710-1. PubMed
  • Ruan PK, Gray RJ. Sensitivity analysis of progression-free survival with dependent withdrawal. Stat Med 2007; 27:1180-98. PubMed
  • Hughes JH, Mason MC, Gray RJ, McLaughlin SA, Degnim AC, Fulmer JT, Pockaj BA, Karstaedt PJ, Roarke MC. A multi-site validation trial of radioactive seed localization as an alternative to wire localization. Breast J 2008; 14:153-7. PubMed
  • Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008; 14:1407-12. PubMed
  • Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, Sandler AB, Schiller JH, Johnson DH. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008; 26:60-5. PubMed
  • Freidlin B, Korn EL, George SL, Gray R. Randomized clinical trial design for assessing noninferiority when superiority is expected. J Clin Oncol 2007; 25:5019-23. PubMed
  • Lew MW, Falabella A, Moore-Jeffries E, Gray RJ, Sullivan MJ. Oncologic emergencies: the anesthesiologist's perspective. J Natl Compr Canc Netw 2007; 5:860-8. PubMed
  • Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K, Nishio M, Brahmer J, Spreafico A, Ludovini V, Massion PP, Dziadziuszko R, Schiller J, Grigorieva J, Tsypin M, Hunsucker SW, Caprioli R, Duncan MW, Hirsch FR, Bunn PA Jr, Carbone DP. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. Journal of the National Cancer Institute 2007; 99:838-46. PubMed
  • Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007; 25:2127-32. PubMed
  • Freidlin B, Korn EL, Hunsberger S, Gray R, Saxman S, Zujewski JA. Proposal for the use of progression-free survival in unblinded randomized trials. J Clin Oncol 2007; 25:2122-6. PubMed
  • Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50. PubMed
  • Gray R, Manola J, Saxman S, Wright J, Dutcher J, Atkins M, Carducci M, See W, Sweeney C, Liu G, Stein M, Dreicer R, Wilding G, DiPaola RS. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group. Clin Cancer Res 2006; 12:1966-9. PubMed
  • Ruan PK, Gray RJ. A method for analyzing disease-specific mortality with missing cause of death information. Lifetime Data Anal 2006; 12:35-51. PubMed
  • Lee ML, Gray RJ, Bj. Generalized rank tests for replicated microarray data. Stat Appl Genet Mol Biol 2006; 4:Article3. PubMed
  • Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP, Gradishar WJ, Pisansky TM, Fetting J, Paietta E, Lazarus HM. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 2003; 349:17-26. PubMed
  • Ibrahim JG, Chen M-H, Gray RJ. Bayesian models for gene expression with DNA microarray data. Journal of American Statistical Association 2002; 97:88-99.
  • Gray RJ, Li Y. Optimal weight functions for marginal proportional hazards analysis of clustered failure time data. Lifetime Data Anal 2002; 8:5-19. PubMed
  • Mutter GL, Baak JP, Fitzgerald JT, Gray R, Neuberg D, Kust GA, Gentleman R, Gullans SR, Wei LJ, Wilcox M. Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation. Gynecol Oncol 2001; 83:177-85. PubMed
  • Goldhirsch A, Gelber RD, Yothers G, Gray RJ, Green S, Bryant J, Gelber S, Castiglione-Gertsch M, Coates AS. Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr 2002. PubMed
  • Gray RJ. Estimation of regression parameters and the hazard function in transformed linear survival models. Biometrics 2000; 56:571-6. PubMed
  • Simpson JF, Gray R, Dressler LG, Cobau CD, Falkson CI, Gilchrist KW, Pandya KJ, Page DL, Robert NJ. Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. J Clin Oncol 2000; 18:2059-69. PubMed
Hide